Up­dat­ed: DICE rolls on as lead oral IL-17 can­di­date meets proof-of-con­cept in PhI tri­al, send­ing shares high­er

DICE Ther­a­peu­tics is now mov­ing for­ward on the next stage of clin­i­cal de­vel­op­ment for its IL-17 can­di­date, on the heels of tout­ing a Phase I win. And in­vestors are re­spond­ing in kind.

DICE re­port­ed topline da­ta Tues­day from a Phase I tri­al en­rolling 104 pa­tients — a mix of healthy vol­un­teers and pso­ri­a­sis pa­tients — test­ing oral small mol­e­cule DC-806, an IL-17 an­tag­o­nist, and gen­er­at­ing safe­ty and phar­ma­co­ki­net­ic da­ta. The study was con­duct­ed in three dif­fer­ent parts: the Phase Ia test­ing a sin­gle as­cend­ing dose in 40 pa­tients, a Phase Ib mul­ti­ple as­cend­ing dose phase in 32 pa­tients, and a Phase Ic proof-of-con­cept test in 32 pa­tients with pso­ri­a­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER